AI assistant
CRISPR Therapeutics AG — Director's Dealing 2018
Jan 30, 2018
30936_dirs_2018-01-30_d7fd7438-b07f-4c6f-bdc0-23857267cf86.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-01-05
Reporting Person: BAYER AKTIENGESELLSCHAFT (10% Owner)
Reporting Person: Bayer Global Investments B.V. (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-01-05 | Common Shares | P | 527472 | $22.75 | Acquired | 5632802 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Shares | 75945 | Indirect |
Footnotes
F1: Represents purchase by Bayer Global Investments B.V. ("Bayer BV"). Bayer BV is the Direct Owner of 5,632,802 common shares of CRISPR Therapeutics AG ("CRISR"). This Form 4 is a joint filing of Bayer BV and Bayer AG. Bayer AG is the 100% Indirect Owner through subsidiaries of the same shares as to which Bayer BV is the Direct Owner.
F2: Reflects shares of CRISR received by a subsidiary of Bayer AG as a pro rata distribution from a limited partnership. Bayer AG is the 100% Indirect Owner through subsidiaries of such shares.